 |
|
Lower Levels of N-Acetylaspartate in Multiple Sclerosis Patients With the Apolipoprotein E  4 Allele
Christian Enzinger, MD;
Stefan Ropele, PhD;
Siegrid Strasser-Fuchs, MD;
Peter Kapeller, MD;
Helena Schmidt, MD;
Birgit Poltrum, MD;
Reinhold Schmidt, MD;
Hans-Peter Hartung, MD;
Franz Fazekas, MD
Arch Neurol. 2003;60:65-70.
Background In multiple sclerosis (MS), the  4 allele of apolipoprotein E (APOE 4) has been associated with more rapid clinical worsening and more severe tissue damage on magnetic resonance imaging.
Objective To use proton magnetic resonance spectroscopy (1H-MRS) to further explore the biochemical changes in the brains of patients with MS associated with APOE 4.
Design A 2-year clinical and 1H-MRS follow-up cohort study.
Setting The MS outpatient clinic, Department of Neurology, and Magnetic Resonance Center of Karl-Franzens University.
Patients We performed 1H-MRS of the central portion of both hemispheres and APOE genotyping in 72 patients (52 women and 20 men; mean ± SD age, 34.8 ± 8.8 years) with clinically definite relapsing-remitting MS. Repeated studies were performed in 44 patients after a mean ± SD interval of 34 ± 9 months.
Main Outcome Measure Levels of N-acetylaspartate as measured by 1H-MRS.
Results Patients with MS and an 4 allele (n = 19) had a significantly lower mean ± SD N-acetylaspartate–creatine ratio than those without an 4 allele (n = 53) (1.73 ± 0.26 vs 1.89 ± 0.24; P = .04) despite the absence of significant differences in age at onset, disease duration, Expanded Disability Status Scale score, and number of previous relapses between subgroups. During follow-up, the drop in the N-acetylaspartate–creatine ratio of 4 carriers was also significantly larger (-0.31 vs -0.10; P = .01). This was paralleled by a higher number of relapses (mean ± SD, 4.1 ± 2.7 vs 1.7 ± 1.6; P = .02) and a faster although nonsignificant progression of disability (mean ± SD  Expanded Disability Status Scale score, 0.9 ± 1.8 vs 0.3 ± 1.1; P = .19).
Conclusions The APOE 4 allele has a negative effect on the course of MS, and increasing axonal damage may be an important mechanism.
From the Department of Neurology (Drs Enzinger, Ropele, Strasser-Fuchs, Kapeller, Poltrum, R. Schmidt, and Fazekas), the Magnetic Resonance Center (Drs Ropele, Kapeller, and Fazekas), and the Institute of Medical Biochemistry (Dr H. Schmidt), Karl-Franzens University, Graz, Austria; and the Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany (Dr Hartung).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
APOE {varepsilon}4 ALLELE IS ASSOCIATED WITH COGNITIVE IMPAIRMENT IN PATIENTS WITH MULTIPLE SCLEROSIS
Mazurek and Shi
Neurology 2008;71:1203-1203.
FULL TEXT
Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox?
Strasser-Fuchs et al.
Mult Scler 2008;14:205-211.
ABSTRACT
Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms
Parmenter et al.
Mult Scler 2007;13:25-32.
ABSTRACT
Influence of Apolipoprotein E {epsilon}4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis
De Stefano et al.
Arch Neurol 2004;61:536-540.
ABSTRACT
| FULL TEXT
Androgens, ApoE, and Alzheimer's Disease
Raber
Sci Aging Knowl Environ 2004;2004:re2-re2.
ABSTRACT
| FULL TEXT
Association of APOE polymorphisms with disease severity in MS is limited to women
Kantarci et al.
Neurology 2004;62:811-814.
ABSTRACT
| FULL TEXT
Reduced N-acetylaspartate Levels and Cognitive Decline
Mazurek
Arch Neurol 2004;61:296-296.
FULL TEXT
New approaches to investigating heterogeneity in complex traits
Bomprezzi et al.
J. Med. Genet. 2003;40:553-559.
ABSTRACT
| FULL TEXT
|
